Cargando…
Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue inf...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065501/ https://www.ncbi.nlm.nih.gov/pubmed/30090839 http://dx.doi.org/10.1093/ofid/ofy168 |